93 related articles for article (PubMed ID: 21273588)
21. Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: therapeutic implications.
Kukreja A; Hutchinson A; Mazumder A; Vesole D; Angitapalli R; Jagannath S; O'connor OA; Dhodapkar MV
Br J Haematol; 2007 Jan; 136(1):106-10. PubMed ID: 17222199
[TBL] [Abstract][Full Text] [Related]
22. Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters.
Clemens J; Seckinger A; Hose D; Theile D; Longo M; Haefeli WE; Burhenne J; Weiss J
Cancer Chemother Pharmacol; 2015 Feb; 75(2):281-91. PubMed ID: 25477008
[TBL] [Abstract][Full Text] [Related]
23. Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1.
Harada D; Yamanaka Y; Ueda K; Nishimura R; Morishima T; Seino Y; Tanaka H
Bone; 2007 Aug; 41(2):273-81. PubMed ID: 17561467
[TBL] [Abstract][Full Text] [Related]
24. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
Roccaro AM; Hideshima T; Raje N; Kumar S; Ishitsuka K; Yasui H; Shiraishi N; Ribatti D; Nico B; Vacca A; Dammacco F; Richardson PG; Anderson KC
Cancer Res; 2006 Jan; 66(1):184-91. PubMed ID: 16397231
[TBL] [Abstract][Full Text] [Related]
25. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
[TBL] [Abstract][Full Text] [Related]
27. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis.
Balsas P; López-Royuela N; Galán-Malo P; Anel A; Marzo I; Naval J
Biochem Pharmacol; 2009 Mar; 77(5):804-12. PubMed ID: 19100720
[TBL] [Abstract][Full Text] [Related]
28. Bortezomib in the front-line treatment of multiple myeloma.
Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451
[TBL] [Abstract][Full Text] [Related]
29. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
[TBL] [Abstract][Full Text] [Related]
30. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
Meister S; Schubert U; Neubert K; Herrmann K; Burger R; Gramatzki M; Hahn S; Schreiber S; Wilhelm S; Herrmann M; Jäck HM; Voll RE
Cancer Res; 2007 Feb; 67(4):1783-92. PubMed ID: 17308121
[TBL] [Abstract][Full Text] [Related]
31. Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma.
Boozari B; Mundt B; Woller N; Strüver N; Gürlevik E; Schache P; Kloos A; Knocke S; Manns MP; Wirth TC; Kubicka S; Kühnel F
Gut; 2010 Oct; 59(10):1416-26. PubMed ID: 20675696
[TBL] [Abstract][Full Text] [Related]
32. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
[TBL] [Abstract][Full Text] [Related]
33. Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.
Frassanito MA; De Veirman K; Desantis V; Di Marzo L; Vergara D; Ruggieri S; Annese T; Nico B; Menu E; Catacchio I; Ria R; Racanelli V; Maffia M; Angelucci E; Derudas D; Fumarulo R; Dammacco F; Ribatti D; Vanderkerken K; Vacca A
Leukemia; 2016 Mar; 30(3):640-8. PubMed ID: 26487273
[TBL] [Abstract][Full Text] [Related]
34. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.
Leung-Hagesteijn C; Erdmann N; Cheung G; Keats JJ; Stewart AK; Reece DE; Chung KC; Tiedemann RE
Cancer Cell; 2013 Sep; 24(3):289-304. PubMed ID: 24029229
[TBL] [Abstract][Full Text] [Related]
35. hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10.
Xi H; Li L; Du J; An R; Fan R; Lu J; Wu YX; Wu SX; Hou J; Zhao LM
Oncol Rep; 2017 Feb; 37(2):961-968. PubMed ID: 28000886
[TBL] [Abstract][Full Text] [Related]
36. Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells.
Meyer AN; McAndrew CW; Donoghue DJ
Cancer Res; 2008 Sep; 68(18):7362-70. PubMed ID: 18794123
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance.
Pollett JB; Trudel S; Stern D; Li ZH; Stewart AK
Blood; 2002 Nov; 100(10):3819-21. PubMed ID: 12393593
[TBL] [Abstract][Full Text] [Related]
38. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells.
Trudel S; Stewart AK; Rom E; Wei E; Li ZH; Kotzer S; Chumakov I; Singer Y; Chang H; Liang SB; Yayon A
Blood; 2006 May; 107(10):4039-46. PubMed ID: 16467200
[TBL] [Abstract][Full Text] [Related]
39. Cell adaptation to activated FGFR3 includes Sprouty4 up regulation to inhibit the receptor-mediated ERKs activation from the endoplasmic reticulum.
Lievens PM; Zanolli E; Garofalo S; Liboi E
FEBS Lett; 2009 Oct; 583(19):3254-8. PubMed ID: 19761767
[TBL] [Abstract][Full Text] [Related]
40. Fibroblast growth factor receptor 3 interacts with and activates TGFβ-activated kinase 1 tyrosine phosphorylation and NFκB signaling in multiple myeloma and bladder cancer.
Salazar L; Kashiwada T; Krejci P; Meyer AN; Casale M; Hallowell M; Wilcox WR; Donoghue DJ; Thompson LM
PLoS One; 2014; 9(1):e86470. PubMed ID: 24466111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]